Alzheimer's Medications

Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s

Digest more

· 15h · on MSN

Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, but don’t call it a failure

Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s.

· 15h · on MSN

Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant

· 10h

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

· 15h

Obesity jab drug fails to slow Alzheimer's

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer's - despite initial hopes that it might help against dementia.

· 16h

Ozempic Pill Flops in Major Trials for Alzheimer’s

· 16h

Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.

· 18h

Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says

The drug was shown to be safe and led to improvements in Alzheimer’s-related biomarkers, the company said, but the treatment did not delay disease progression.

· 17h

Novo Nordisk: Semaglutide's Success In Alzheimer's Was Unlikely

· 20h

Novo Nordisk slides as Ozempic pill fails to slow Alzheimer’s disease progression in large trials

14hon MSN

Weight-Loss Drugs Don’t Appear to Work Against Alzheimer’s

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the drugs affect the body beyond just weight loss. But one of the more anticipated studies exploring how they impact Alzheimer’s disease has found no meaningful effect, Novo Nordisk said in a press release on Nov. 24

MedPage Today on MSN

Highly Anticipated Alzheimer's Trials Yield Disappointing Results for GLP-1 Drug

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug Discovery Foundation in New York City, a nonprofit group that supported earlier research of the GLP-1 receptor agonist liraglutide (Victoza, Saxenda) in Alzheimer's disease.

ConsumerAffairs

Weight-loss drug falls short in Alzheimer’s study

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving bio